Paladin, Quest Pharma deal

Quest issued 3.5 million shares to Paladin under a 2009 deal that gave Quest five mAbs against cancer antigens. The shares are valued at C$140,000 (US$137,382) based on Quest's close of C$0.04 on Oct....